MNMichael R. Narkewicz

Michael R. Narkewicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael R. Narkewicz has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Ronald J. Sokol

    Department of Pediatrics, The Pediatric Liver Center, The Children's Hospital, University of Colorado School of Medicine, Denver, CO 80218, USA

    3 shared publications
  • Gayle Jones

    Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine and the Children’s Hospital, Denver, CO 80218, USA

    2 shared publications
  • Angela Lorts

    1 shared publication
  • Arlene V. Drack

    University of Iowa, Iowa City, IA, United States

    1 shared publication
  • Arvind Kasaragod

    Department of Pediatrics, The Pediatric Liver Center, The Children's Hospital, University of Colorado School of Medicine, Denver, CO 80218, USA

    1 shared publication
  • Baruch Yerushalmi

    1 shared publication

Latest Publications

  • Ophthalmologic Complications in Children With Chronic Hepatitis C Treated With Pegylated Interferon

    by Michael R Narkewicz, Philip Rosenthal, Kathleen B Schwarz, Arlene Drack, Todd Margolis, Michael X Repka, PEDS‐C Study Group

    Objectives: Interferon treatment for chronic viral hepatitis C (HCV) has been associated with the development of retinopathy in 19% to 29% of adults. Our purpose is to describe the ophthalmologic complications of pegylated interferon‐α2a with either placebo or ribavirin in children with chronic HCV (the PEDS‐C trial).Materials and Methods: Prospective, comprehensive ophthalmologic examinations including slit lamp at enrollment and after 24 and 48 weeks of treatment of 114 children participating in a randomized clinical trial.Results: One hundred and twenty‐eight children were screened for entry, of whom 123 had an eye examination and no child had existing retinal disease. One hundred fourteen children were eligible and were treated. One hundred ten children had an eye examination at 24 weeks and 103 children at 48 weeks. Three of 114 subjects (2.6%) developed documented (n = 2) or possible (1) serious eye complications. One subject developed evidence of ischemic retinopathy (cotton‐wool spots) by week 24, 1 developed uveitis by week 48, and 1 reported at week 48 transient (<4 hours) monocular blindness that had occurred at week 36 with a subsequent normal examination at week 48.Conclusions: Ophthalmologic complications are infrequent in children who are treated with pegylated interferon‐α2a for HCV (2%–3%). Because of the potential severity of ischemic retinopathy and uveitis, prospective ocular assessment should remain part of the monitoring strategy for children who are treated with interferon for HCV.


  • Open Access

    Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist

    by Scott Canna, Jennifer Frankovich, Gloria Higgins, Michael R Narkewicz, S Russell Nash, J Roger Hollister, Jennifer B Soep, Leonard L Dragone

    Purpose: We investigated the etiology of acute hepatitis in three children with systemic Juvenile Idiopathic Arthritis (sJIA) taking Interleukin-1 receptor antagonist (IL1RA). Methods: Laboratory and clinical data for three children with sJIA diagnosed at ages 13 months to 8 years who developed acute hepatitis during treatment with IL1RA were reviewed for evidence of sJIA flare, infection, macrophage activation syndrome (MAS), malignancy, and drug reaction. Results: In all patients, hepatitis persisted despite cessation of known hepatotoxic drugs and in absence of known infectious triggers, until discontinuation of IL1RA. Liver biopsies had mixed inflammatory infiltrates with associated hepatocellular injury suggestive of an exogenous trigger. At the time of hepatitis, laboratory data and liver biopsies were not characteristic of MAS. In two patients, transaminitis resolved within one week of discontinuing IL1RA, the third improved dramatically in one month. Conclusions: Although sJIA symptoms improved significantly on IL1RA, it appeared that IL1RA contributed to the development of acute hepatitis. Hepatitis possibly occurred as a result of an altered immune response to a typical childhood infection while on IL1RA. Alternatively, hepatitis could have represented an atypical presentation of MAS in patients with sJIA taking IL1RA. Further investigation is warranted to determine how anti-IL1 therapies alter immune responsiveness to exogenous triggers in patients with immune dysfunction such as sJIA. Our patients suggest that close monitoring for hepatic and other toxicities is indicated when treating with IL1RA.


  • Evaluation of a Scoring System for Assessing Prognosis in Pediatric Acute Liver Failure

    by Brandy R. Lu, Jane Gralla, Edwin Liu, Emily L. Dobyns, Michael R. Narkewicz, Ronald J. Sokol


  • Connective tissue growth factor expression is increased in biliary epithelial cells in biliary atresia

    by Michael R. Narkewicz, Arvind Kasaragod, M. Scott Lucia, Sean Pflummer, Ronald J. Sokol, Kurt R. Stenmark


  • Hepatic Dysfunction Following the Fontan Procedure

    by Michael R. Narkewicz, Henry M. Sondheimer, James W. Ziegler, Yvonne Otanni, Angela Lorts, Elizabeth M. Shaffer, J. Gerard Horgan, Ronald J. Sokol

    The Fontan procedure offers a palliation for the hemodynamic derangements associated with congenital heart lesions characterized by a single functional ventricle, but it causes a chronically elevated systemic venous pressure that may result in hepatic congestion. The objective of this study was to characterize hepatic function and its relationship to cardiac function in children who had undergone the Fontan procedure. In a cross-sectional study of 11 children aged 38 months to 216 months (mean, 149 months), the authors evaluated indices of cardiac and hepatic function, including galactose clearance, Doppler hepatic ultrasonography, synthetic function, and markers of liver injury, at 9 months to 176 months (mean, 100 months) after children had undergone the Fontan procedure. The most common biochemical abnormality of hepatic function was a prolongation of the prothrombin time and a low factor V level. There was a trend toward progressive abnormality in prothrombin time with increasing interval since the Fontan procedure. Galactose elimination half-life and galactose elimination capacity were inversely correlated with the time after Fontan (R 2 = 0.65, P = 0.004). There was no relationship between cardiac functional measurements and liver function. Prothrombin time and galactose elimination half-life are abnormal in children who have undergone the Fontan procedure and may be useful markers of hepatic function in the longitudinal assessment of these patients.


  • Biliary atresia: an update on our understanding of the disorder

    by Michael R. Narkewicz

    Biliary atresia is the leading cause of cholestasis in infants younger than 3 months. It is also the leading indication for liver transplantation in children. This review focuses on recent advances in the etiology, diagnosis, and management of biliary atresia.


  • LARGE VOLUME PARACENTESIS IN THE MANAGEMENT OF ASCITES IN THE PEDIATRIC POPULATION

    by Robert E. Kramer, Ronald J. Sokol, Baruch Yerushalmi, Henry R. Thompson, Edward J. Hoffenberg, Michael R. Narkewicz

  • Open Access

    Correction of Hypozincemia Following Liver Transplantation in Children Is Associated With Reduced Urinary Zinc Loss

    by Michael R. Narkewicz, Nancy Krebs, Frederick Karrer, Kathy Orban-Eller, Ronald J. Sokol

    Zinc deficiency is a relatively common problem in children with chronic liver disease. We have previously shown inappropriate urinary zinc excretion in children with chronic liver disease and hypozincemia. This study was designed to determine if zinc deficiency and inappropriate urinary zinc losses are corrected in children with liver disease by liver transplantation. Thirty–three patients (age 1–19 years) underwent 35 liver transplants for acute and chronic liver disease. At the time of transplant, 17 patients had low plasma zinc (hypozincemic) (plasma zinc, 45.4 ± 1.8 μg/dL), whereas 18 had normal plasma zinc (75.7 ± 3.8). Before transplant, patients with zinc deficiency had higher urinary zinc to creatinine ratio compared with those with normal zinc status (6.6 ± 1.9 vs. 2.2 ± 0.6; P = .03) and lower serum albumin concentrations (low: 2.8 ± 0.1 vs. normal: 3.3 ± 0.2; P = .02). After transplant, there was a significant reduction in urinary zinc losses in the hypozincemic group followed by normalization of plasma zinc levels by 7 days posttransplant. These data suggest that the abnormal renal zinc homeostasis that is present in approximately 50% of pediatric patients undergoing liver transplant is rapidly improved and biochemical zinc deficiency is reversed after liver transplantation.


  • Cysteine Supplementation and Reduction of Total Parenteral Nutrition—Induced Hepatic Lipid Accumulation in the Weanling Rat

    by Michael R. Narkewicz, Sherrie Caldwell, Gayle Jones

    Summary Total parenteral nutrition (TPN)-induced hepatic steatosis is the most common complication of TPN administration to humans. The mechanism of TPN-induced hepatic steatosis has not been studied in young mammals. The goal of this study was to determine the mechanism of TPN-induced hepatic steatosis in the weanling rat and the effect of supplementation of TPN with choline and/or cysteine on TPN-induced hepatic steatosis. In the weanling rat, we investigated the effect of TPN administration on histologic hepatic steatosis, total hepatic lipid, hepatic acetyl-CoA-carboxylase (ACC—the rate limiting enzyme in fatty acid synthesis) specific activity, and total plasma lipids. TPN administration resulted in a threefold increase in hepatic lipid as compared with control and sham animals (TPN 138 ± 12 mg/g liver versus control 57 ± 1), an increase in histologic steatosis (TPN 3.7 versus control 1.3), and a decline in total plasma lipid (TPN 2.1 ± 0.3 g/L versus control 4.1 ± 0.3). TPN-induced hepatic steatosis in the weanling rat was not associated with an increase in ACC specific activity (TPN 2.10 ± 0.33 nmol/min/mg protein versus control 2.85 ± 0.23). Supplementation of the TPN with choline (15 mg/day) did not significantly lessen hepatic steatosis; however, supplementation of TPN with cysteine (2.5 mg/day) or with cysteine and choline did result in a significant lessening of hepatic lipid content and of histologic steatosis and a normalization of total plasma lipid. Tritiated glycerol incorporation into media lipids secreted by hepatocytes isolated from TPN-treated animals was 45% of that from cysteine-supplemented animals, suggesting a defect in hepatic lipid secretion associated with TPN-induced hepatic steatosis in the weanling rat that is partially corrected by cysteine supplementation.